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Abstract
The Ikaros family of DNA binding proteins are critical regulators of lymphocyte differentiation. In 
multipotent hematopoietic progenitors, Ikaros supports transcriptional priming of genes promoting 
lymphocyte differentiation. Ikaros targets the Nucleosome Remodeling Deacetylase complex 
(NuRD) to lymphoid lineage genes, thereby increasing chromatin accessibility and transcriptional 
priming. After lymphoid lineage specification, Ikaros expression is raised to levels characteristic 
of intermediate B cell and T cell precursors, which is necessary to support maturation and prevent 
leukemogenesis. Loss of Ikaros in T cell precursors allows the NuRD complex to repress 
lymphocyte genes and extends its targeting to genes that support growth and proliferation, causing 
their activation and triggering a cascade of events that leads to leukemogenesis. Loss of Ikaros in 
B cell precursors blocks differentiation and perpetuates stromal adhesion by enhancing integrin 
signaling. The combination of integrin and cytokine signaling in Ikaros-deficient pre-B cells 
promotes their survival and self-renewal. The stages of lymphocyte differentiation that are highly 
dependent on Ikaros are underscored by changes in Ikaros transcription, supported by a complex 
network of stage-specific regulatory networks that converge upon the Ikzf1 locus. It is increasingly 
apparent that understanding the regulatory networks that operate upstream and downstream of 
Ikaros is critical not only for our understanding of normal lymphopoiesis, but also in placing the 
right finger on the mechanisms that support hematopoietic malignancies in mouse and human.
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Introduction
Ikaros is an essential regulator of lymphocyte differentiation with two major contributions in 
this developmental system. The first is in early hematopoietic progenitors where it provides 
lymphoid lineage differentiation potential. The second is at the proliferative stages of T and 
B cell precursor differentiation in mediating transition to a quiescent state where 
recombination of the second antigen receptor chain and selection of the T and B cell 
repertoire takes place. A stepwise increase in Ikaros expression at key developmental stages, 
i.e. in lymphoid lineage restricted progenitors and lymphocyte precursors, is required for 
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Ikaros to perform its unique roles in the hemo-lymphoid pathways. Loss of Ikaros activity 
results in profound differentiation defects and leukemic transformation of B and T cell 
precursors. Studies of Ikaros function in mouse models and human GWAS studies are 
providing support for the involvement of Ikaros not only in normal lymphocyte 
differentiation but also in the development of high risk leukemias caused by IKZF1 
mutations. Here we will review past and recent studies that together provide new insight into 
the mechanisms by which Ikaros contributes to normal lymphocyte differentiation and its 
aberrant manifestations.
Structure-function of Ikaros and its family members
Ikaros [1,2] and its family members are Krupple-type zinc-(Zn-) finger proteins with two 
highly conserved Zn-finger domains at their N- and C-terminus (Fig. 1a). The N-terminal 
Zn-finger domain is comprised of four highly conserved Zn-fingers encoded by exons three 
though five that support sequence specific DNA-binding. The second and third Zn-fingers of 
the N-terminal domain are required to provide sequence specific binding to a core motif A/
GGGAA [3-5] and are indispensable for lymphocyte differentiation [6-8]. A recent study 
has revealed that the first and fourth Ikaros zinc fingers make distinct contributions to 
lymphoid development or leukemogenesis, suggesting that these two fingers alter the overall 
sequence specificity and gene targets [9].
Chromatin enrichment studies on the Ikaros proteins in lymphocytes provided strong 
selection for the core motif AGGAA that was previously predicted as an Ikaros binding site 
both by modeling the amino acid composition of Kruppel type Zn-fingers 2 and 3 and by in 
vitro DNA binding site selection studies with Ikaros proteins [3,5,10,11]. Interestingly, the 
Ikaros DNA binding specificity on chromatin is similar to that described for a variety of Ets 
factors on lymphoid specific regulatory elements [12]. Ikaros chromatin enrichment sites 
and motifs are found in both enhancers and promoters with relative distributions dependent 
on cell type. At T cell specific enhancers, the most frequent partners of Ikaros are the E-box 
E2A proteins and Runx1, supporting a functional interaction between these factors during T 
cell differentiation [10] (Fig. 1b).
The Ikaros C-terminal domain contains two Zn-fingers encoded by exon eight and is 
required for oligomerization with self and other family members (Aiolos, Helios and Eos) 
[13-16]. Oligomerization increases Ikaros DNA binding activity in vitro and is critical for 
Ikaros function in vivo [13,17].
A number of Ikaros isoforms can be generated by differential splicing of exons three to eight 
[3,4,13]. This is in part due to non-canonical splice acceptor sites at exons four, six and 
seven. The major Ikaros isoforms encountered from the early to the late stages of hemo-
lymphopoiesis are the DNA binding isoforms Ik-1 and Ik-2 (Fig. 1a), whereas splicing 
variants lacking the N-terminal Zn-fingers and unable to bind DNA are normally produced 
at very low frequency[4,14,15]. However, genomic alterations and deletions of the Zn-finger 
encoding exons cause an increase in the frequency of isoforms that lack DNA binding 
activity (e.g. Ik-6) (reviewed by ref. [18]). These interfere with the activity of DNA-binding 
Ikaros isoforms and family members by competing for incorporation into the Nucleosome 
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Remodeling Histone Deacetylase (NuRD) chromatin remodeling complex [19-24] and are 
frequently referred to as Ikaros dominant negative (dn) (Fig. 1a, c) [6,13].
Ikaros is an integral component of the NuRD complex in lymphocytes
Biochemical purification of Ikaros proteins has identified a stable association with the 
2MDa NuRD complex in the nucleus of both lymphocytes and erythroleukemia cells 
[23-25] (Fig. 1c). The major components of the NuRD complex are HDAC1, HDAC2, 
MTA1, MTA2, MBD3, Rbp46/48, and Mi-2β. Mi-2β is a 220kDa ATP-dependent 
chromatin remodeler that modulates the topology of the chromatin by sliding nucleosomes 
relative to DNA [26,27] (Fig. 1c). Unlike Ikaros whose expression is largely limited to the 
hematopoietic system, components of the NuRD complex are ubiquitously expressed.
Mouse genetic studies investigating the transcriptional properties of Ikaros and Mi-2β, a 
unique component of the NuRD complex, have provided dual functions for the Ikaros-
NuRD complex as a repressor as well as an activator of gene expression through its histone 
deactylase and nucleosome remodeling activities [10,25,28-31]. Although Ikaros and Mi-2β 
are in the same complex, antagonistic interactions have been observed such as in the 
regulation of Cd4 expression as well as in the cell fate decisions of the HSC [30,31]. Down-
regulation of the stem cell self-renewing genes (e.g. Mpl, Tek, Ndn, Mdmdc2, Tgm2, Ebi3) 
and the early myeloid promoting genes (e.g. Csf1r, Egr1, Il6ra, Il6st) in Mi-2β deficient 
HSC correlates with the loss of self-renewal leading to transient expansion and exhaustion 
of the HSC as well as impaired differentiation into the myeloid lineage[31]. Given that 
Ikaros down-regulates the stem cell program in the lymphoid-primed multi-potent 
progenitor (LMPP, see the following section) and up-regulates lymphoid programs in the 
HSC and LMPP, Ikaros and Mi-2β may have opposing roles on the regulation of stem cell 
self-renewal as well as in cell fate decisions towards the lymphoid versus myeloid pathways 
in the earliest lympho-myeloid progenitors.
Recent studies on genome-wide chromatin mapping and gene expression profiling have 
provided new mechanistic insights into the function of Ikaros in the NuRD complex [10]. In 
wild-type DP thymocytes, Mi-2β binding sites are largely limited to where Ikaros binds to 
the genome. In these cells, the Ikaros-NuRD complex binds to active genes that are 
members of pathways that support lymphocyte differentiation. Reduction in Ikaros proteins 
increases chromatin access to the NuRD complex resulting in increased nucleosome 
remodeling and histone deacetylation with subsequent loss in lymphoid gene expression. In 
addition, the NuRD complex is re-distributed to transcriptionally poised genes located in 
permissive chromatin, causing activation of these genes, frequently by interfering with local 
activity of the Polycomb repressive complex. Many of these poised genes are associated 
with cell growth, proliferation, migration and metabolism such as those of the Notch 
signaling pathway [10,32](Fig. 1d). This is likely the underlying cause of the developmental 
block and malignant transformation of Ikaros mutant DP thymocytes and provides the 
mechanism by which Ikaros serves as a tumor suppressor by antagonizing NuRD complex 
chromatin remodeling activities both directly at lymphoid-specific genes and indirectly at 
growth and proliferation promoting genes.
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Priming lymphoid potential in multi-potent progenitors; the first task
The first restriction that a multi-potent HSC undergoes towards becoming a lymphocyte 
produces an LMPP in the bone marrow (Fig. 2a). We and others have independently 
identified the LMPP using either the cell surface receptor Flt3 or an Ikaros-based reporter 
that is strongly up-regulated from the HSC to the LMPP [33-35]. The LMPP has robust 
lymphoid and myeloid differentiation potential and minimal potential for erythroid and 
megakaryocyte differentiation. Further restrictions along the lymphoid pathways give rise to 
the early lymphoid precursor (ELP) [36] [37], the common lymphoid progenitor (CLP) [38] 
and the early thymic precursor (ETP) [39]. These further differentiate into pro-B and double 
negative 2 (DN2) pro-T cell precursors, respectively (Fig. 2a).
The human counterpart of the LMPP was also identified in CD34+ cord blood cells and as a 
source of CD34+ acute myeloid leukemia (AML), providing support for a key role in human 
hemo-lymphopoiesis and in leukemogenesis [40-42]. This revised road map of early 
hematopoiesis first described in the mouse is highly conserved in the human indicating the 
importance of mouse genetic models for the study of normal hematopoiesis and lymphoid 
disorders in the human.
Studies on mouse genetic models have revealed that while Ikaros is not required for 
development of the LMPP, it is critical for its ability to differentiate into lymphoid restricted 
progenitors such as the CLP and the ETP [34,39], the generation of which usually identifies 
with lymphoid lineage specification. Notably, the E2A transcription factor is also involved 
in lymphoid priming and shares many down-stream targets [10,43,44]. However, E2A may 
also acts upstream of Ikaros as it is required for the development of the LMPP from the 
multi-potent HSC [43]. These genetic studies are in line with biochemical studies that have 
identified E2A DNA binding motifs in the context of Ikaros chromatin enrichment sites in 
lymphoid specific enhancers[10].
While pro-B and NK are completely absent in Ikaros null mice, the ETP (DN1) in the 
thymus is still detected albeit at a highly reduced level [39]. Contribution of other Ikaros 
family members, such as Helios expressed in the HSC and through early stages of T cell but 
not B cell differentiation may provide some rescue in T cell differentiation. Ikaros dn mice 
show more profound defects with no T cell progenitors detected indicating interference with 
Helios function [6].
Priming of lymphoid specific gene expression in multi-potent progenitors
The establishment of lineage restriction can be observed at the molecular level by the 
induction and propagation of lineage-affiliated transcriptional programs that support lineage-
specific differentiation. Comparative analyses of genome-wide transcriptional profiles of the 
HSC, LMPP, GMP and megakaryocyte-erythrocyte progenitor (MEP) [45] established nine 
lineage-affiliated signatures that fit into two transcriptional cascades that originate in the 
HSC [44]. One is propagated in the erythroid pathway, while the other, in the lympho-
myeloid pathways (Fig. 2b, c). The front-runner in the lympho-myeloid cascade is a “stem-
myeloid-lymphoid” (s-myly) signature, that is composed of genes primed in the HSC and 
further up-regulated in the LMPP. The second runner is a “restricted-myeloid-lymphoid” (r-
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myly) signature that comprises of genes primed in the LMPP and further induced in the 
downstream myeloid and lymphoid progenitors [44] (Fig. 2b, c).
Progenitor comparative transcriptional analysis has revealed that progenitor commitment 
into the lymphoid or myeloid lineages is gradual, whereas commitment into the erythroid 
lineage is rapid. Notably, the lymphoid and myeloid potential and their supporting gene 
expression programs are both maintained in the nominal myeloid progenitor (GMP) and B 
cell progenitor (CLP, pro-B) populations [44,46,47] The latent T cell activity of the GMP 
observed in vitro in mice and human [40,44] is consistent with the remaining expression of 
lymphoid genes in these cells (Fig. 2a, b). Although these progenitors may not support 
lymphoid differentiation in vivo, this study supports the idea of progressive lineage 
restriction along the lymphoid or myeloid pathways where either B cell or T cell potential is 
lost first followed by myeloid potential [48-50]. A similar approach to transcriptional 
profiling and computational analyses on human HSC and progenitors have likewise revealed 
transcriptional ‘landscapes’ that cross the lineage and population boundaries [42].
The multi-lineage (erythroid, myeloid and lymphoid) priming in the HSC observed by 
clustering of lineage specific gene expression profiles has been further confirmed at the 
single cell level. Erythroid and myeloid gene expression programs are primed together with 
lymphoid gene expression at a similar frequency, suggesting there is equal opportunity for 
all three fates that is further modulated by environmental inputs [44]. Lineage specific 
priming occurs in cells with an active stem cell gene expression program that is rapidly 
extinguished upon lineage restriction (Fig. 2b).
Transcriptional analyses of Ikaros null HSC and progenitors have revealed that up-
regulation of the lymphoid genetic program and down-regulation of stem cell and myeloid 
programs controlled by Ikaros underlie this critical stage of lymphoid lineage specification 
at the LMPP stage [44] (Fig. 2c). A failure of such events results in a block of differentiation 
towards CLP and ETP and augmentation of the myeloid differentiation from the LMPP 
[34,44]. Examples of Ikaros target genes during this process are summarized in Fig. 2c. It 
will be important to determine whether maintenance of stem cell gene expression in mutant 
myeloid progenitors can contribute to aberrant expansion and whether this is linked to 
myeloid proliferative disorders in human. Thus the first major role of Ikaros in early multi-
potent progenitors is to awaken their lymphoid potential by increasing local chromatin 
accessibility through the NuRD complex while suppressing alternate fates of myeloid 
differentiation and self-renewal.
Proliferative expansion of lymphocyte precursors is harnessed by Ikaros
After lymphoid lineage specification, Ikaros expression is again increased at the small pre-B 
cell stage in the bone marrow and in double positive (DP) T cell precursors in the thymus. 
These are equivalent stages of B and T cell differentiation where precursor cells come out of 
cycle to undergo the second antigen receptor rearrangement and selection (Fig. 2a). Notably, 
when Ikaros activity is reduced in human and mice, B and T cell leukemias arise from the 
preceding proliferative stages (Fig. 3a). Thus Ikaros plays an important role as a tumor 
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suppressor at the lymphoid precursor stages where proliferation and Rag expression provide 
a high risk for leukemic transformation.
Studies using germline knock-out mouse models have shown that homozygocity for Ikaros 
null and heterozygocity for Ikaros dn mutations result in a rapid development of T-ALL 
with a thymic origin. Leukemogenesis kinetics are faster in cells with the Ikaros dn isoforms 
due to interference with other Ikaros family members such as Helios and Aiolos that are also 
expressed in these cells [6,17]. One of the mechanisms of leukemic transformation in the 
thymus may relate to altered TCR signaling [51,52]. Recent studies have revealed that 
Ikaros suppresses Notch-dependent leukemia development by directly repressing 
transcription of Notch1 through upstream regulatory elements and promoters that include a 
cryptic intragenic promoter in DP thymocytes that supports expression of a ligand-
independent Notch signaling [32,53,54]. Deletion of Ikaros in DP thymocytes unleashes de-
regulated Notch signaling in these cells.
A new high-risk model of B-ALL supported by Ikaros mutations
Acute lymhoblastic leukemias (ALLs) are neoplasms of lymphoid precursors and are 
common among childhood malignancies [55]. With the advent of high-resolution genome-
wide profiling approaches, a variety of genetic alterations, deletions and mutations have 
been newly identified on the ALL genomes that cooperate with previously characterized 
chromosomal alterations [56-58]. Notably, deletions and mutations in the genes encoding 
key transcription factors for early lymphoid development (e.g. PAX5, IKZF1, IKZF3, EBF, 
TCF3 and LEF) were identified in 40% of B-ALL cases [56]. Among these factors, deletion 
and mutation in the IKZF1 locus that encodes IKAROS is highly associated with BCR-
ABL1-positive B-ALL that display poor prognosis [57]. These genetic alterations either give 
rise to functionally dominant negative IKAROS isoforms or result in haploinsufficiency. 
Both of these types of mutations can contribute to leukemia development.
Conditional inactivation of the Ikzf1 exon 5 (IkE5Δ/Δ), encoding N-terminal zinc fingers two 
and three, from the CLP or pro-B stages in mice resulted in production of dn isoforms and 
an arrest of B cell differentiation at the proliferative large pre-B stage [8] (Fig. 3a). Unlike 
WT counterparts, IkE5Δ/Δ large pre-B cells require BM stromal co-culture for survival and 
growth. Transcriptional profiling and functional analyses of IkE5Δ/Δ large pre-B cells 
revealed augmented integrin-mediated signaling that supports stable association with bone 
marrow stroma, survival and self-renewal [8] (Fig. 3b).
Inhibition of integrin-signaling by focal adhesion kinase (FAK) inhibitors induces the 
detachment of IkE5Δ/Δ large pre-B cells from BM stroma and apoptosis of mutant cells both 
in vitro and in vivo [8]. Immunodeficient mice transplanted with the IkE5Δ/Δ large pre-B 
cells develop oligoclonal pre-B-ALLs indicating selection of additional changes for 
malignant transformation [8]. These studies reveal a novel mechanism by which IKZF1 
mutations contribute to poor prognosis pre-B-ALL that extends beyond the developmental 
block also generated by mutations in other lineage specific transcriptional regulators. Pre-B 
cell interactions with bone marrow niches are tightly controlled by Ikaros and provide a new 
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target for therapeutic intervention in poor prognosis B-ALL associated with IKZF1 
mutations.
A conditional Ikzf1 null mouse model that deletes exon eight gave a similar block in pre-B 
cell differentiation with accumulation of “aberrant pro-B” cells that are phenotypically 
similar to large pre-B cells [59]. Also in this mouse model, pre-BCR signaling is defective 
and cell adhesion programs of mutant pro-B cells are augmented. However, these mutant 
cells show a proliferation defect [59]. The differences between these two studies may be 
attributed to differences in the loss of Ikaros DNA binding activities; up-regulated Aiolos in 
the conditional Ikaros null mutant cells may compensate for the loss of Ikaros and prevent 
aberrant proliferative expansion that results upon loss of both Ikaros and Aiolos activities 
caused by the Ikaros dn isoforms generated by the IkE5Δ/Δ allele.
Transcriptional regulation of the Ikaros gene
The Ikzf1 (IKZF1) locus spans over 120kb on chromosome 11 in mice (Fig. 4a) and 7p in 
human in a highly conserved genomic locus. Deletions or loss of function mutations in the 
IKZF1 locus has been detected at a high frequency in a precursor B-ALL (20-30%), 
especially in over 80% of BCR-ABL+ B-ALL and nearly 70% of blast crisis of chronic 
myelogenous leukemia (CML) [56,57]. Large or smaller deletions at the 7p arm resulting in 
the loss of the entire IKZF1 allele, other null alleles or producing dn isoforms (IK-6), have 
been reported in B-ALL [18,60]. Mutations within the N-terminal Zn-finger domain that 
generate functional dn forms have been detected in human T-ALL and early T-cell precursor 
(ETP)-ALL [58,61] These studies show a strong correlation between Ikaros 
haploinsufficiency as well as expression of dn isoforms and ALL development that is 
strongly supported by past and recent mouse models.
Thus, an understanding of the mechanisms that support Ikaros expression at stages of 
lymphocyte development that are dependent on Ikaros activity is critical. Our biochemical 
and genetic studies on Ikzf1 regulation have established the activities of hemo-lymphoid 
stage-specific promoters and enhancers at the Ikzf1 locus. Of the two promoters identified, 
one is the major promoter in lymphoid-myeloid cells (Fig. 4a, b). Of the six enhancers active 
in lymphoid and myeloid cells, only two enhancers are active in T cells and only one is 
responsible for up-regulation of Ikaros expression during the transition from the HSC to the 
LMPP [34,62,63](Fig. 4a, b). Several known transcription factors (TFs) important in the 
lymphoid system, such as E-box proteins, TCF-1, Runx1 and Ikaros itself, have been shown 
to bind these Ikaros locus regulatory regions in vivo [63]. Thus Ikzf1 expression is likely 
regulated by a complex regulatory network of cis-regulatory elements targeted by key 
lymphoid lineage promoting transcription factors. Further investigation on the functional 
contribution of these regulatory elements and TFs and the signaling events supporting their 
activation may provide a handle to understand and manipulate Ikaros expression during 
development and in hematopoietic malignancies such as multiple myeloma [64,65].
Recent studies revealed an unexpected role of IKAROS and AIOLOS in multiple myeloma 
(MM). Ikaros proteins in MM cells are targets of lenalidomide, a salidomide-like drug [66] 
that binds ubiquitin E3 ligase and alters its specificity, thereby promoting Ikaros protein 
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degradation [64,65]. This suggests that in MM cells unlike B-ALL, the presence rather than 
the absence of Ikaros proteins promotes proliferation. Other mechanisms are also possible. 
Aiolos proteins are required for the generation of high affinity long-lived plasma cells, 
resident in the bone marrow and responsible for long-term humoral immunity. However, 
loss of Aiolos does not interfere with generation and affinity maturation of short-lived 
plasma cells suggesting an effect on the self-renewing potential of this long-lived effector 
cell population [67]. Importantly, these long-lived high affinity plasma cells are the normal 
counterparts from which MM is derived [68] [69].
Conclusions and future directions
The balanced production of lymphocytes is important for organismal health. Disruption of 
the mechanisms that support this process can cause disorders ranging from immune cell 
deficiencies to cancers of hematopoietic but also non-hematopoietic cell origin. Ikaros 
activity in the HSC–MPP identifies with lymphoid lineage potential, while Ikaros activity at 
later stages of lymphocyte differentiation regulates normal proliferative expansion and 
differentiation to a non-proliferative stage. Deletions and mutations in the IKZF1 locus in 
both coding and non-coding regions (i.e. highly conserved regulatory regions) may interfere 
with IKAROS activity and provide several independent ways to support leukemia 
development.
Past studies on Ikaros in lymphocyte differentiation are paving the road to new studies that 
seek to delineate Ikaros-based regulatory and signaling networks in both normal 
development and immune cell based disease. As such these studies bear important 
therapeutic implications for human health.
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Figure 1. Schematic representation of the Ikaros isoforms, DNA binding motifs and of the 
Ikaros-NuRD complex and its mode of action in lymphocytes
(a) Exon composition containing Zn finger motifs involved in DNA binding and protein 
dimerization is shown for Ikaros isoforms and Ikaros family members (Aiolos, Helios and 
Eos). Exons are shown as light blue boxes. Dark blue bars indicate zinc fingers. (b) 
Transcription factor binding motifs identified in the vicinity of Ikaros enrichment peaks at 
enhancer regions in thymocytes. Two highly enriched Ikaros binding motifs identified by de 
novo motif search on its chromatin binding sites. (c) Structure of the Ikaros-NuRD complex 
and of Mi-2β. The NuRD complex contains Class I histone deacetylases (HDAC1/2) and the 
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ATP-dependent chromatin remodeler Mi-2β (and α). (d) A model of negative and positive 
regulation by the NuRD complex. Targeting of the Mi-2β–NuRD complex to permissive 
chromatin (H3K4me3, H3K9Ac) is restricted to lymphoid genes by the Ikaros family 
proteins. Our hypothesis is that NuRD’s repressive activities are poised by Ikaros extensive 
DNA binding at its target sites. Upon reduction in Ikaros activity either through 
posttranslational modification of the protein or through Ikaros inactivating mutations 
increases chromatin access of the Mi-2β–NuRD complex and loss of lymphoid gene 
expression. Upon loss of Ikaros, the NuRD complex also re-distributes to new sites 
associated with promoters of transcriptionally poised genes that support cell growth, 
proliferation and metabolism causing their activation in part by displacing the PRC2 
complex. Ik, Ikaros; Aio, Aiolos; polII, RNA polymerase II; PRC, polycomb repressive 
complex.
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Figure 2. Cellular and transcriptional hierarchies in early hematopoiesis
(a) The lineage potential of each progenitor in the hematopoietic hierarchy is denoted by 
letter size. B, B cells; T, T cells; E, erythroid; M, myeloid. Relative changes in Ikaros 
expression in this developmental hierarchy is shown at the bottom. Red arrows indicate 
critical stages where Ikaros family proteins are up-regulated. (b) The two cascades of 
lineage specific gene programs that originate in the multi-potent HSC and segregate within 
the erythroid and lympho-myeloid, pathways are shown. The early lympho-myeloid cascade 
is comprised of two layers of gene expression, the s-myly is primed in the HSC and further 
induced in the LMPP and downstream progeny whereas r-myly is primed in the LMPP. In 
sharp contrast, only one layer is seen in the early erythroid cascade reflecting a lack of 
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progressive lineage restriction points. (c) Effects of Ikaros deficiency on the stem and s-
myly signatures. A heatmap of gene expression of the s-myly and stem cell signatures in the 
HSC, LMPP, GMP, MEP and proB from WT and Ikaros null mice is shown. The signature 
designation is provided on the right side. The red bars indicate the up-regulated genes and 
the green bar indicates the down-regulated genes upon loss of Ikaros. The leg of the s-myly 
signature that is down-regulated is highly enriched for lymphoid promoting genes, whereas 
the middle section of the s-myly signature that is up-regulated is highly enriched for myeloid 
promoting growth factors and transcription regulators. Examples of the deregulated genes 
are provided in each box.
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Figure 3. Effects of Ikaros mutations in early lymphoid development and homeostasis
(a) A summary of Ikaros’ roles in early lymphocyte differentiation as revealed by various 
mouse genetic models. ΔIk, germline Ikaros null mutation; Ikdn. germline Ikaros dominant 
negative mutation; IkE5Δ/Δ, B cell specific conditional Ikaros dominant negative mutation. 
(b) A diagram of interactions between integrin, IL-7R and pre-BCR signaling in WT large 
pre-B cells and the effects of an Ikaros dominant negative mutation (IkE5Δ/Δ) on this 
signaling network. The strength of the effect of individual signaling pathways on cellular 
properties such as survival, self-renewal and proliferation is depicted by letter size. Green 
arrows and red bars indicate positive and negative interactions respectively. pFAK, 
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phosphorylated FAK; IL-7R, Interleukin-7 receptor; GHR, growth factor and/or cytokine 
receptor.
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Figure 4. A summary of regulatory elements, their activities and stage specificity at the Ikaros 
gene (Ikzf1)
(a) A summary of the activities of the regions tested in transgenic mouse models (C, D, E, F, 
G, H, I, J) at the Ikzf1 locus [34,62,63]. Two promoter regions (A and B) and a promoter 
element (p) are shown. (b) A diagram of the activities of the lympho-myeloid promoter B 
and enhancers during lymphopoiesis. Promoter B (+p) provides Ikaros expression in the 
HSC, B cells, myeloid and DN1-3 thymocytes, however, enhancers J, E, F, H, I are required 
to maintain the expression in restricted chromatin environments. The enhancer C(D) is 
required for up-regulation of Ikaros from the HSC to the LMPP and it can further maintain 
the expression throughout T cell development. Although enhancer H cannot provide activity 
in the LMPP, it can support the expression past DN3 stages.
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